Description
The miRNA research field is of interest for the future and is now well established that miRNAs represent new potential therapeutic targets as well as relevant diagnostic / prognostic biomarkers.
Nearly 60% of patients with non-small cell lung cancer are resistant to cisplatin, a first-line anti-cancer agent.The research teams in this project have identified a specific miRNA as a genetic factor involved in these resistances.
MiR-X is both a biomarker that can predict resistance to chemotherapy and a new therapeutic target allowing combined treatment against lung cancer.
Benefits:
- Diagnosis: Predictive biomarker of response for patients treated with cisplatin allowing a dedicated treatment. Biomarker monitoring the effectiveness of this same treatment.
- Therapeutic: Improved response rate to cisplatin in patients with non-small cell lung cancer.